Jianhong Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianhong Fu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Depei Wu
Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, China
5 shared publicationsJindan Kong
Intensive Care Medicine Department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
5 shared publicationsJun Wang
Department of Intensive Care Medicine the First Affiliated Hospital of Soochow University Suzhou China
4 shared publicationsDi Zou
Department of Critical Care Medicine The Affiliated Infectious Diseases Hospital of Soochow University Suzhou China
3 shared publicationsShan Wan
Department of Pathology School of Biology and Basic Medical Sciences Soochow University Suzhou China
3 shared publicationsYan Xie
Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology
3 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1728965
Clinical characteristics and prognostic impact of Burkholderia cepacia complex colonization and infection in patients with hematologic malignancies
Objective: In recent years, there has been an increasing number of reports on infections caused by the Burkholderia cepacia complex (Bcc). However, the clinical characteristics and prognosis of Bcc infections in patients with hematological malignancies remain unreported. This study aimed to delineate the clinical trajectory from colonization to active infection and to identify prognostic factors influencing outcomes in hematologic malignancy patients with Bcc colonization. Methods: We conducted a retrospective analysis of 185 hematological malignancy patients with Bcc colonization at the Department of Hematology, The First Affiliated Hospital of Soochow University, from November 2019 to November 2022. This study aimed to identify independent risk factors for mortality in this patient population. Results: Respiratory failure ( P < 0.001), hepatic insufficiency ( P < 0.001), renal insufficiency ( P = 0.001), and post-colonization infections ( P = 0.01) were significantly associated with adverse prognosis in Bcc-colonized hematological malignancy patients. Post-colonization infections emerged as an independent risk factor for poor prognosis (HR = 2.855, 95%CI 1.214–6.715, P = 0.016). Subgroup analysis revealed that hematopoietic stem cell transplantation (HSCT) recipients with post-colonization infections had particularly poor outcomes (HR = 3.733, 95%CI 1.179–11.824, P = 0.025). Conclusion: Progression from Bcc colonization to active infection, particularly in HSCT recipients, signifies a critical juncture with markedly increased mortality. Implementing vigilant surveillance protocols to prevent this transition is paramount for improving survival in this vulnerable population.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1728965
Open AccessClinical characteristics and prognostic impact of Burkholderia cepacia complex colonization and infection in patients with hematologic malignancies
Objective: In recent years, there has been an increasing number of reports on infections caused by the Burkholderia cepacia complex (Bcc). However, the clinical characteristics and prognosis of Bcc infections in patients with hematological malignancies remain unreported. This study aimed to delineate the clinical trajectory from colonization to active infection and to identify prognostic factors influencing outcomes in hematologic malignancy patients with Bcc colonization. Methods: We conducted a retrospective analysis of 185 hematological malignancy patients with Bcc colonization at the Department of Hematology, The First Affiliated Hospital of Soochow University, from November 2019 to November 2022. This study aimed to identify independent risk factors for mortality in this patient population. Results: Respiratory failure ( P < 0.001), hepatic insufficiency ( P < 0.001), renal insufficiency ( P = 0.001), and post-colonization infections ( P = 0.01) were significantly associated with adverse prognosis in Bcc-colonized hematological malignancy patients. Post-colonization infections emerged as an independent risk factor for poor prognosis (HR = 2.855, 95%CI 1.214–6.715, P = 0.016). Subgroup analysis revealed that hematopoietic stem cell transplantation (HSCT) recipients with post-colonization infections had particularly poor outcomes (HR = 3.733, 95%CI 1.179–11.824, P = 0.025). Conclusion: Progression from Bcc colonization to active infection, particularly in HSCT recipients, signifies a critical juncture with markedly increased mortality. Implementing vigilant surveillance protocols to prevent this transition is paramount for improving survival in this vulnerable population.
- Open Access
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1613414
Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China
Purpose: Patients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological diseases.Methods: A retrospective study was conducted on hematological diseases patients diagnosed as sepsis and treated with CMS at the First Affiliated Hospital of Soochow University between November 2021 and July 2023. Demographics, clinical presentation, causative organisms, clinical outcomes and adverse events (AEs) were recorded. The univariate and multivariate analysis was conducted to identify predictive factors for clinical effectiveness and renal insufficiency.Results: A total of 81 hematological patients diagnosed with sepsis were included, the mean (change in sequential organ failure assessment [SOFA] score) ΔSOFA when utilizing CMS was 3.90 ± 2.10. Following CMS treatment, a clinical effectiveness rate was observed in 62.96% of patients, while the bacteriological eradication rate was 60.23%. Additionally, the 28-day all-cause mortality rate was 29.63%. The median length of stay in the ICU and total in-hospital stay was 13.5 and 33 days, respectively. AEs were reported in 16 patients (19.75%), including 15 (18.52%) renal insufficiency, 1 (1.23%) hepatic insufficiency, and 1 (1.23%) rash. The multivariate analysis of clinical effectiveness indicated that a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score, a higher Charlson comorbidity index, the relapse or refractory of hematological diseases, septic shock, and the use of mechanical ventilation was independently associated with a poor clinical effectiveness. The univariate analysis of renal insufficiency demonstrated that allogeneic hematopoietic stem cell transplantation, aplastic anemia, and gastrointestinal infection had a statistically significant impact on renal function.Conclusions: The findings of our study demonstrated that CMS was an efficacious treatment for sepsis in Chinese patients with hematological diseases, while concurrently exhibiting an acceptable toxicity profile.
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1613414
Open AccessColistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China
Purpose: Patients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological diseases.Methods: A retrospective study was conducted on hematological diseases patients diagnosed as sepsis and treated with CMS at the First Affiliated Hospital of Soochow University between November 2021 and July 2023. Demographics, clinical presentation, causative organisms, clinical outcomes and adverse events (AEs) were recorded. The univariate and multivariate analysis was conducted to identify predictive factors for clinical effectiveness and renal insufficiency.Results: A total of 81 hematological patients diagnosed with sepsis were included, the mean (change in sequential organ failure assessment [SOFA] score) ΔSOFA when utilizing CMS was 3.90 ± 2.10. Following CMS treatment, a clinical effectiveness rate was observed in 62.96% of patients, while the bacteriological eradication rate was 60.23%. Additionally, the 28-day all-cause mortality rate was 29.63%. The median length of stay in the ICU and total in-hospital stay was 13.5 and 33 days, respectively. AEs were reported in 16 patients (19.75%), including 15 (18.52%) renal insufficiency, 1 (1.23%) hepatic insufficiency, and 1 (1.23%) rash. The multivariate analysis of clinical effectiveness indicated that a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score, a higher Charlson comorbidity index, the relapse or refractory of hematological diseases, septic shock, and the use of mechanical ventilation was independently associated with a poor clinical effectiveness. The univariate analysis of renal insufficiency demonstrated that allogeneic hematopoietic stem cell transplantation, aplastic anemia, and gastrointestinal infection had a statistically significant impact on renal function.Conclusions: The findings of our study demonstrated that CMS was an efficacious treatment for sepsis in Chinese patients with hematological diseases, while concurrently exhibiting an acceptable toxicity profile.
- 24 February 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (3) , 1-4
Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade
- 24 February 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (3) , 1-4
Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade
- 5 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1219-1226
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
Summary: Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is considered the standard of treatment for individuals with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. We conducted a retrospective analysis that encompassed 16 critically ill patients newly diagnosed with AML who were admitted to the intensive care unit (ICU) and received the VEN and HMA regimen. Among them, 13 were primary AML, and three were MDS‐transformed AML. The mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18.9, and the mean sepsis‐related organ failure assessment score (SOFA) was 6.2. The average length of the ICU stay was 27.3 days. The median duration of VEN administration was 16 days. After the first course of VEN + HMA, 12 cases (75%) achieved complete remission (CR) or CR with incomplete haematological recovery (CRi). Among the five patients harbouring TP53 mutations, the overall response rate (ORR) was 90%. All patients experienced grade 3–4 haematological adverse events (AEs). With a median follow‐up of 9.5 months (range: 0.5–23), the overall survival (OS) rate was 43.75%. TP53‐wild patients and CR state after the first course of VEN–HMA indicated better survival. The combination of VEN and HMA has demonstrated a significantly elevated therapeutic response rate in newly diagnosed AML patients with critical illness.
- 5 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1219-1226
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
Summary: Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is considered the standard of treatment for individuals with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. We conducted a retrospective analysis that encompassed 16 critically ill patients newly diagnosed with AML who were admitted to the intensive care unit (ICU) and received the VEN and HMA regimen. Among them, 13 were primary AML, and three were MDS‐transformed AML. The mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18.9, and the mean sepsis‐related organ failure assessment score (SOFA) was 6.2. The average length of the ICU stay was 27.3 days. The median duration of VEN administration was 16 days. After the first course of VEN + HMA, 12 cases (75%) achieved complete remission (CR) or CR with incomplete haematological recovery (CRi). Among the five patients harbouring TP53 mutations, the overall response rate (ORR) was 90%. All patients experienced grade 3–4 haematological adverse events (AEs). With a median follow‐up of 9.5 months (range: 0.5–23), the overall survival (OS) rate was 43.75%. TP53‐wild patients and CR state after the first course of VEN–HMA indicated better survival. The combination of VEN and HMA has demonstrated a significantly elevated therapeutic response rate in newly diagnosed AML patients with critical illness.
- Open Access
- 27 December 2023
- Published by Elsevier in Asia-Pacific Journal of Oncology Nursing
- Vol. 11 (3) , 100368
Management of neurotoxicity syndrome complicated by autologous hematopoietic stem cell transplantation bridge to chimeric antigen receptor T-Cell therapy: A case report
- 27 December 2023
- Published by Elsevier in Asia-Pacific Journal of Oncology Nursing
- Vol. 11 (3) , 100368
Open AccessManagement of neurotoxicity syndrome complicated by autologous hematopoietic stem cell transplantation bridge to chimeric antigen receptor T-Cell therapy: A case report
- Open Access
- 20 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating the identification of additional CAR-T targets. Here, we show that FcRH5 is expressed on multiple myeloma cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells elicited antigen-specific activation, cytokine secretion and cytotoxicity against MM cells. Moreover, FcRH5 CAR-T cells exhibited robust tumoricidal efficacy in murine xenograft models, including one deficient in BCMA expression. We also show that different forms of soluble FcRH5 can interfere with the efficacy of FcRH5 CAR-T cells. Lastly, FcRH5/BCMA-bispecific CAR-T cells efficiently recognized MM cells expressing FcRH5 and/or BCMA and displayed improved efficacy, compared with mono-specific CAR-T cells in vivo. These findings suggest that targeting FcRH5 with CAR-T cells may represent a promising therapeutic avenue for MM.
- 20 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessChimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating the identification of additional CAR-T targets. Here, we show that FcRH5 is expressed on multiple myeloma cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells elicited antigen-specific activation, cytokine secretion and cytotoxicity against MM cells. Moreover, FcRH5 CAR-T cells exhibited robust tumoricidal efficacy in murine xenograft models, including one deficient in BCMA expression. We also show that different forms of soluble FcRH5 can interfere with the efficacy of FcRH5 CAR-T cells. Lastly, FcRH5/BCMA-bispecific CAR-T cells efficiently recognized MM cells expressing FcRH5 and/or BCMA and displayed improved efficacy, compared with mono-specific CAR-T cells in vivo. These findings suggest that targeting FcRH5 with CAR-T cells may represent a promising therapeutic avenue for MM.
- Open Access
- 11 June 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (7) , e24547
Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population
Introduction: Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE). However, cardiovascular complications remain essential causes of mortality in patients with refractory TTP, while the association of cardiac biomarkers with the prognosis of TTP warrants further investigation.Methods: Patients admitted to the First Affiliated Hospital of Soochow University for refractory TTP from 2013 through 2020 were included in this retrospective study. Clinical characteristics were collected from electronic health records. Biomarker levels on admission and post TPE were recorded. Logistic regression was adopted to identify risk factors for mortality.Results: A total of 78 patients with refractory TTP were included in this study. Twenty‐one patients died during hospitalization, with a mortality rate of 26.9%. High‐sensitivity cardiac troponin T (hs‐cTnT), N‐terminal probrain natriuretic peptide (NT‐proBNP), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ratios (AAR) were increased in deceased patients compared with the survival group. Multivariate analysis showed that AAR after TPE was associated with overall mortality (OR: 4.45, 95% CI 1.09–18.19). The areas under the receiver operator characteristic curve (AUC) of AAR, hs‐cTnT, and NT‐proBNP for the association with mortality were 0.814, 0.840, and 0.829, respectively.Conclusion: Higher post‐TPE cardiac biomarker levels are associated with increased in‐hospital mortality in patients with refractory TTP.
- 11 June 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (7) , e24547
Open AccessPrognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population
Introduction: Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE). However, cardiovascular complications remain essential causes of mortality in patients with refractory TTP, while the association of cardiac biomarkers with the prognosis of TTP warrants further investigation.Methods: Patients admitted to the First Affiliated Hospital of Soochow University for refractory TTP from 2013 through 2020 were included in this retrospective study. Clinical characteristics were collected from electronic health records. Biomarker levels on admission and post TPE were recorded. Logistic regression was adopted to identify risk factors for mortality.Results: A total of 78 patients with refractory TTP were included in this study. Twenty‐one patients died during hospitalization, with a mortality rate of 26.9%. High‐sensitivity cardiac troponin T (hs‐cTnT), N‐terminal probrain natriuretic peptide (NT‐proBNP), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ratios (AAR) were increased in deceased patients compared with the survival group. Multivariate analysis showed that AAR after TPE was associated with overall mortality (OR: 4.45, 95% CI 1.09–18.19). The areas under the receiver operator characteristic curve (AUC) of AAR, hs‐cTnT, and NT‐proBNP for the association with mortality were 0.814, 0.840, and 0.829, respectively.Conclusion: Higher post‐TPE cardiac biomarker levels are associated with increased in‐hospital mortality in patients with refractory TTP.
- Open Access
- 11 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (12) , e24100
Comparative study of hematological and radiological feature of severe/critically ill patients with COVID‐19, influenza A H7N9, and H1N1 pneumonia
Objectives: This study aimed to explore clinical indexes for management of severe/critically ill patients with COVID‐19, influenza A H7N9, and H1N1 pneumonia by comparing hematological and radiological characteristics.Methods: Severe/critically ill patients with COVID‐19, H7N9, and H1N1 pneumonia were retrospectively enrolled. The demographic data, clinical manifestations, hematological parameters, and radiological characteristics were compared.Results: In this study, 16 cases of COVID‐19, 10 cases of H7N9, and 13 cases of H1N1 who met severe/critically ill criteria were included. Compared with COVID‐19, H7N9 and H1N1 groups had more chronic diseases (80% and 92.3% vs. 25%,p < 0.05), higher APACHE Ⅱ scores (16.00 ± 8.63 and 15.08 ± 6.24, vs. 5.50 ± 2.58,p < 0.05), higher mortality rates (40% and 46.2% vs. 0%,p < 0.05), significant lymphocytopenia (0.59 ± 0.31 × 109/L and 0.56 ± 0.35 × 109/L vs. 0.97 ± 0.33 × 109/L,p < 0.05), and elevated neutrophil‐to‐lymphocyte ratio (NLR; 14.67 ± 6.10 and 14.64 ± 10.36 vs. 6.29 ± 3.72,p < 0.05). Compared with the H7N9 group, ground‐glass opacity (GGO) on chest CT was common in the COVID‐19 group (p = 0.028), while pleural effusion was rare (p = 0.001).Conclusions: The NLR can be used as a clinical parameter for the predication of risk stratification and outcome in COVID‐19 and influenza A pneumonia. Manifestations of pleural effusion or GGO in chest CT may be helpful for the identification of different viral pneumonia.
- 11 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (12) , e24100
Open AccessComparative study of hematological and radiological feature of severe/critically ill patients with COVID‐19, influenza A H7N9, and H1N1 pneumonia
Objectives: This study aimed to explore clinical indexes for management of severe/critically ill patients with COVID‐19, influenza A H7N9, and H1N1 pneumonia by comparing hematological and radiological characteristics.Methods: Severe/critically ill patients with COVID‐19, H7N9, and H1N1 pneumonia were retrospectively enrolled. The demographic data, clinical manifestations, hematological parameters, and radiological characteristics were compared.Results: In this study, 16 cases of COVID‐19, 10 cases of H7N9, and 13 cases of H1N1 who met severe/critically ill criteria were included. Compared with COVID‐19, H7N9 and H1N1 groups had more chronic diseases (80% and 92.3% vs. 25%,p < 0.05), higher APACHE Ⅱ scores (16.00 ± 8.63 and 15.08 ± 6.24, vs. 5.50 ± 2.58,p < 0.05), higher mortality rates (40% and 46.2% vs. 0%,p < 0.05), significant lymphocytopenia (0.59 ± 0.31 × 109/L and 0.56 ± 0.35 × 109/L vs. 0.97 ± 0.33 × 109/L,p < 0.05), and elevated neutrophil‐to‐lymphocyte ratio (NLR; 14.67 ± 6.10 and 14.64 ± 10.36 vs. 6.29 ± 3.72,p < 0.05). Compared with the H7N9 group, ground‐glass opacity (GGO) on chest CT was common in the COVID‐19 group (p = 0.028), while pleural effusion was rare (p = 0.001).Conclusions: The NLR can be used as a clinical parameter for the predication of risk stratification and outcome in COVID‐19 and influenza A pneumonia. Manifestations of pleural effusion or GGO in chest CT may be helpful for the identification of different viral pneumonia.
- Open Access
- 28 October 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin’s Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation
Background: Among the growing number of patients with hematologic neoplasms hospitalized in the intensive care unit (ICU), the largest proportion of these patients are diagnosed with lymphoma. However, less attention has been paid in the past to identifying critically ill patients and assessing the prognosis of patients in ICU. Traditional critical care-related scores have shown limitations and inaccuracy in predicting mortality risk. Methods: Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) were searched for in the Marketplace for Information in Intensive Care Medicine III (MIMIC-III) database. We searched mortality within 28 days as the primary endpoint. Logistics regression was used to screen risk factors. A calibration curve was used for internal validation, and the ROC curve and AUC were used to compare the new model with traditional scores. Results: 405 patients with DLBCL are enrolled in the project. Multivariate analysis shows the patients with the level of lactate dehydrogenase (LDH) > 327 U/L had an increased risk of 28-day mortality in ICU than others (OR = 13.04, pConclusions: The elevated level of LDH indicates a poor prognosis of patients with DLBCL in the ICU. Our risk score with crossed validation based on the level of LDH shows a significant prognostic value and may be a valuable tool for assessing the critically ill as well.
- 28 October 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessElevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin’s Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation
Background: Among the growing number of patients with hematologic neoplasms hospitalized in the intensive care unit (ICU), the largest proportion of these patients are diagnosed with lymphoma. However, less attention has been paid in the past to identifying critically ill patients and assessing the prognosis of patients in ICU. Traditional critical care-related scores have shown limitations and inaccuracy in predicting mortality risk. Methods: Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) were searched for in the Marketplace for Information in Intensive Care Medicine III (MIMIC-III) database. We searched mortality within 28 days as the primary endpoint. Logistics regression was used to screen risk factors. A calibration curve was used for internal validation, and the ROC curve and AUC were used to compare the new model with traditional scores. Results: 405 patients with DLBCL are enrolled in the project. Multivariate analysis shows the patients with the level of lactate dehydrogenase (LDH) > 327 U/L had an increased risk of 28-day mortality in ICU than others (OR = 13.04, pConclusions: The elevated level of LDH indicates a poor prognosis of patients with DLBCL in the ICU. Our risk score with crossed validation based on the level of LDH shows a significant prognostic value and may be a valuable tool for assessing the critically ill as well.
- Open Access
- 12 February 2021
- Published by Springer Nature in Research Square
Comparative Study of Hematological and Radiological Feature of Severe/Critically Ill Patients with COVID-19, Influenza A H7N9 and H1N1 Pneumonia
Objectives This study aimed to explore useful clinical indexes for management of severe/critically ill patients with COVID-19, Influenza A H7N9 and H1N1 pneumonia by comparing hematological and radiological characteristics between them. Methods Severe/critically ill patients with confirmed diagnosis of COVID-19, Influenza A H7N9 and H1N1 pneumonia were retrospectively enrolled. The demographic data, clinical manifestations, hematological parameters, and radiological characteristics of three groups were compared. The influenza A was divided into two groups with/without patient death.Results In this study, 16 cases of COVID-19, 10 cases of influenza A (H7N9), and 13 cases of influenza A (H1N1) who met severe/critically ill criteria were included. Compared with COVID-19, the Influenza A (H7N9 and H1N1) groups had relatively more chronic diseases (80% and 92.3% vs 25%, P<0.05), higher APACHE Ⅱ scores (16.00 ± 8.63 and 15.08 ± 6.24, vs 5.50 ± 2.58, P<0.05) and higher mortality rates (40% and 46.2% vs 0%, P<0.05). The hematological finding indicated that Influenza A H7N9 and H1N1 patients had more significant lymphocytopenia (0.59 ± 0.31 × 109/L and 0.56 ± 0.35 × 109/L vs 0.97 ± 0.33 × 109/L, P < 0.05), elevated neutrophil to lymphocyte ratio (NLR; 14.67 ± 6.10 and 14.64 ± 10.36 vs 6.29 ± 3.72, P < 0.05) compared to COVID-19. Especially in influenza A patients, NLR was significant different between the patients with or without death. Compared with the H7N9 group, ground glass opacity (GGO) on chest CT was more common in the COVID-19 group (P = 0.028), while pleural effusion was relatively rare (P = 0.001).ConclusionCompared to COVID-19, patients with Influenza A (H7N9 and H1N1) had more underlying chronic diseases and higher mortality rates. The NLR can be used as a clinical parameter for the predication of risk stratification and outcome in COVID-19 and Influenza A pneumonia. Manifestations of pleural effusion or GGO in chest CT may be helpful for the identification of different viral pneumonia.
- 12 February 2021
- Published by Springer Nature in Research Square
Open AccessComparative Study of Hematological and Radiological Feature of Severe/Critically Ill Patients with COVID-19, Influenza A H7N9 and H1N1 Pneumonia
Objectives This study aimed to explore useful clinical indexes for management of severe/critically ill patients with COVID-19, Influenza A H7N9 and H1N1 pneumonia by comparing hematological and radiological characteristics between them. Methods Severe/critically ill patients with confirmed diagnosis of COVID-19, Influenza A H7N9 and H1N1 pneumonia were retrospectively enrolled. The demographic data, clinical manifestations, hematological parameters, and radiological characteristics of three groups were compared. The influenza A was divided into two groups with/without patient death.Results In this study, 16 cases of COVID-19, 10 cases of influenza A (H7N9), and 13 cases of influenza A (H1N1) who met severe/critically ill criteria were included. Compared with COVID-19, the Influenza A (H7N9 and H1N1) groups had relatively more chronic diseases (80% and 92.3% vs 25%, P<0.05), higher APACHE Ⅱ scores (16.00 ± 8.63 and 15.08 ± 6.24, vs 5.50 ± 2.58, P<0.05) and higher mortality rates (40% and 46.2% vs 0%, P<0.05). The hematological finding indicated that Influenza A H7N9 and H1N1 patients had more significant lymphocytopenia (0.59 ± 0.31 × 109/L and 0.56 ± 0.35 × 109/L vs 0.97 ± 0.33 × 109/L, P < 0.05), elevated neutrophil to lymphocyte ratio (NLR; 14.67 ± 6.10 and 14.64 ± 10.36 vs 6.29 ± 3.72, P < 0.05) compared to COVID-19. Especially in influenza A patients, NLR was significant different between the patients with or without death. Compared with the H7N9 group, ground glass opacity (GGO) on chest CT was more common in the COVID-19 group (P = 0.028), while pleural effusion was relatively rare (P = 0.001).ConclusionCompared to COVID-19, patients with Influenza A (H7N9 and H1N1) had more underlying chronic diseases and higher mortality rates. The NLR can be used as a clinical parameter for the predication of risk stratification and outcome in COVID-19 and Influenza A pneumonia. Manifestations of pleural effusion or GGO in chest CT may be helpful for the identification of different viral pneumonia.